We use cookies on our website. Carry on browsing if you’re happy with this or find out more



MD Anderson and Kymab partnership

MD Anderson article

Kymab and the University of Texas MD Anderson announce a strategic cancer drug discovery and development alliance.

The alliance, between the University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit and Kymab, the leading human monoclonal antibody biopharmaceutical company, seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers.

Kymouse™ — Kymab’s human antibody discovery platform — has unparalleled diversity as it yields antibodies with highly attractive drug-like properties, and is able to rapidly identify and enrich rare high-quality molecules that can be explored as novel therapeutics.

"Together, Kymab and MD Anderson bring power and skills to a partnership committed to efficiency and speed in delivering novel immunotherapies through the use of world-class science," said David Chiswell, Chairman and CEO of Kymab. "Immuno-oncology is an exceptionally promising field of research and a key focus for Kymab."

The agreement will use each partner’s complementary skills, resources and capabilities to develop innovative new drugs for cancer. The collaboration will combine Kymab’s industry-leading antibody platform, in-house discovery and development experience together with MD Anderson’s novel target biology, clinical datasets, translational and clinical infrastructure to develop products to clinical proof of concept and ultimately for submission for FDA approval.

"These are exciting times for the development of monoclonal antibodies for cancer immunotherapy, " said Carlo Toniatti, MD, PhD, Executive Director of ORBIT. "This alliance presents a great opportunity to leverage our translational and clinical expertise, and develop innovative antibody drugs vital to helping patients in their fight against cancer."

The collaboration will focus on developing novel monoclonal antibodies as well as on identifying biomarkers for identification of responder populations. The agreement is for an initial period of five years.

Notes to Editors

About MD Anderson Cancer Center and ORBIT

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospital’s” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

ORBIT (Oncology Research for Biologics and Immunotherapy Translation) platform is a novel centralized organization within MD Anderson, Houston, Texas, with the mission of making MD Anderson a recognized leader in the discovery and development of novel monoclonal antibodies. The ORBIT team focuses on combining scientific excellence with industry standard and is committed to accelerate and execute the translation of novel discoveries into clinically relevant anti-cancer mAbs. ORBIT’s scientific directors are Jeffrey J. Molldrem, M.D., professor of the Department of Stem Cell Transplantation and Cellular Therapy and Michael Curran, Ph.D., professor of the Department of Immunology. 


Kymab, Kymouse are trademarks of Kymab Limited.

Find out which events we'll be attending this year

View events